BRIEF—Health Canada added approval for Tafinlar plus Mekinist combo

Pharma regulator Health Canada has approved the use of a combination of two Novartis cancer therapies as targeted treatment to prevent recurrence of melanoma following surgery, also referred to as adjuvant treatment.

The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) has been approved for the adjuvant treatment of patients with BRAF V600 mutation melanoma and involvement of lymph nodes, following complete surgical removal of the tumors.

"Novartis is very pleased to bring this targeted combination therapy to Canadians with this serious form of skin cancer," said Isabelle Deslauriers, franchise head, solid tumors, oncology, Novartis Pharmaceuticals Canada.

"Part of our commitment to reimagine cancer care is the ongoing development of our innovative therapies. One out of every two Canadians will get cancer in their lifetimeand we are committed to bringing new options, so they may live longer and better lives," she added.

Combination use of Tafinlar plus Mekinist is already approved by Health Canada to treat patients with unresectable or metastatic melanoma who have a BRAF V600 mutation.